Aballi John's Form 4 filing
Exagen Inc. (XGN) · filed Nov 18, 2024
- Accession no.
- 0001274737-24-000094
- Filed
- Nov 18, 2024
- Trade date
- Nov 14, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $68.3K. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001274737-25-000009 (Feb 25, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aballi JohnCIK 0001843113 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | Common Stock | PPurchaseAcquired | +24,305 | $2.81F1 | +$68,297.05 | 689,799 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.72 to $2.94, inclusive. The reporting person undertakes to provide Exagen Inc., any security holder of Exagen Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this form 4.
Referenced by the price of 1 transaction in Table I.